Technical Analysis for ZLAB - Zai Lab Limited

Grade Last Price % Change Price Change
B 151.68 4.20% 6.12
ZLAB closed up 4.2 percent on Thursday, May 13, 2021, on 88 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical ZLAB trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 4.20%
180 Bearish Setup Bearish Swing Setup 4.20%
Stochastic Reached Oversold Weakness 4.20%
Multiple of Ten Bearish Other 4.20%
Oversold Stochastic Weakness 4.20%
50 DMA Support Bullish 1.08%
Earnings Movers Other 1.08%
Older End-of-Day Signals for ZLAB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
50 DMA Support about 17 hours ago
50 DMA Resistance about 17 hours ago
60 Minute Opening Range Breakdown about 18 hours ago
1.5x Volume Pace about 21 hours ago
Up 5% about 21 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Natural Sciences Medication Chemical Substances Omadacycline

Is ZLAB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 193.54
52 Week Low 62.89
Average Volume 547,851
200-Day Moving Average 120.76
50-Day Moving Average 146.37
20-Day Moving Average 160.78
10-Day Moving Average 154.52
Average True Range 8.83
ADX 15.93
+DI 18.72
-DI 27.46
Chandelier Exit (Long, 3 ATRs ) 151.40
Chandelier Exit (Short, 3 ATRs ) 164.17
Upper Bollinger Band 179.66
Lower Bollinger Band 141.91
Percent B (%b) 0.26
BandWidth 23.48
MACD Line 0.16
MACD Signal Line 2.77
MACD Histogram -2.6115
Fundamentals Value
Market Cap 13.35 Billion
Num Shares 88 Million
EPS -3.12
Price-to-Earnings (P/E) Ratio -48.68
Price-to-Sales 268.12
Price-to-Book 20.60
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 163.39
Resistance 3 (R3) 162.56 157.83 161.43
Resistance 2 (R2) 157.83 154.85 158.24 160.78
Resistance 1 (R1) 154.75 153.01 156.29 155.58 160.13
Pivot Point 150.03 150.03 150.79 150.44 150.03
Support 1 (S1) 146.95 147.04 148.49 147.78 143.23
Support 2 (S2) 142.22 145.20 142.64 142.58
Support 3 (S3) 139.15 142.22 141.93
Support 4 (S4) 139.97